VivoSeq
Oncology

Advanced or Recurrent Solid Tumors

2

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Advanced or Recurrent Solid Tumors is an early-stage landscape with 2 programs across 5 companies. The most active players are BeiGene, Bristol-Myers Squibb, GSK.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BeiGene logo

BeiGene

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalOno Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

EVM16

Peking University

Tislelizumab

BeiGene

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

10

clinical trials

Recruiting4 · 40%
Completed4 · 40%
Terminated1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Recruiting·BBio-Path Holdings, Inc.·Phase 1·NCT04196257·50 enrolled
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Recruiting·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 1·NCT06816108·60 enrolled
Advanced or Recurrent Solid Tumors Treated With SHetA2
Recruiting·UUniversity of Oklahoma·Phase 1·NCT04928508·50 enrolled
A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors
Recruiting·PPeking University·Phase 1·NCT06541639·78 enrolled
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT01591356·49 enrolled
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Completed·Pfizer logoPfizer·Phase 1·NCT01286987·113 enrolled
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
Completed·—·Phase 1·NCT00098514·53 enrolled
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT02593786·58 enrolled
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT03195478·37 enrolled
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
Terminated·GSK logoGSK·Phase 1·NCT02630251·5 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)